South Korea
· Delayed Price · Currency is KRW BL Pharmtech Statistics
Total Valuation
BL Pharmtech has a market cap or net worth of KRW 33.99 billion. The enterprise value is 34.64 billion.
| Market Cap | 33.99B |
| Enterprise Value | 34.64B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BL Pharmtech has 88.97 million shares outstanding. The number of shares has increased by 0.50% in one year.
| Shares Outstanding | 88.97M |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.83% |
| Owned by Institutions (%) | n/a |
| Float | 65.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.04 |
| PB Ratio | 1.12 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.81 |
| EV / Sales | 2.07 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -175.72 |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.13 |
| Quick Ratio | 0.88 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -25.88 |
| Interest Coverage | -5.37 |
Financial Efficiency
Return on equity (ROE) is -30.72% and return on invested capital (ROIC) is -6.45%.
| Return on Equity (ROE) | -30.72% |
| Return on Assets (ROA) | -5.15% |
| Return on Capital (ROIC) | -6.45% |
| Revenue Per Employee | 1.11B |
| Profits Per Employee | 213.55M |
| Employee Count | 15 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.03 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.31% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.31% |
| 50-Day Moving Average | 467.88 |
| 200-Day Moving Average | 475.84 |
| Relative Strength Index (RSI) | 27.25 |
| Average Volume (20 Days) | 147,595 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BL Pharmtech had revenue of KRW 16.71 billion and earned 3.20 billion in profits. Earnings per share was 35.92.
| Revenue | 16.71B |
| Gross Profit | 10.08B |
| Operating Income | -5.74B |
| Pretax Income | -10.39B |
| Net Income | 3.20B |
| EBITDA | -4.87B |
| EBIT | -5.74B |
| Earnings Per Share (EPS) | 35.92 |
Balance Sheet
The company has 4.75 billion in cash and 5.10 billion in debt, giving a net cash position of -354.74 million or -3.99 per share.
| Cash & Cash Equivalents | 4.75B |
| Total Debt | 5.10B |
| Net Cash | -354.74M |
| Net Cash Per Share | -3.99 |
| Equity (Book Value) | 30.59B |
| Book Value Per Share | 340.39 |
| Working Capital | 843.63M |
Cash Flow
In the last 12 months, operating cash flow was 754.93 million and capital expenditures -952.07 million, giving a free cash flow of -197.14 million.
| Operating Cash Flow | 754.93M |
| Capital Expenditures | -952.07M |
| Free Cash Flow | -197.14M |
| FCF Per Share | -2.22 |
Margins
Gross margin is 60.30%, with operating and profit margins of -34.33% and 19.17%.
| Gross Margin | 60.30% |
| Operating Margin | -34.33% |
| Pretax Margin | -62.15% |
| Profit Margin | 19.17% |
| EBITDA Margin | -29.15% |
| EBIT Margin | -34.33% |
| FCF Margin | -1.18% |
Dividends & Yields
BL Pharmtech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.50% |
| Shareholder Yield | -0.50% |
| Earnings Yield | 9.40% |
| FCF Yield | -0.58% |
Stock Splits
The last stock split was on February 5, 2010. It was a forward split with a ratio of 1.1.
| Last Split Date | Feb 5, 2010 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
BL Pharmtech has an Altman Z-Score of -1.13. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.13 |
| Piotroski F-Score | n/a |